nach oben

Zeitschrift für Gerontologie und Geriatrie

Erschienen in:

12.04.2017 | Beiträge zum Themenschwerpunkt

Translation of imaging biomarkers from clinical research to healthcare

verfasst von: Dr. Ingo Kilimann, Jochen René Thyrian, Wolfgang Hoffmann, Stefan J. Teipel

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Sonderheft 2/2017

Einloggen, um Zugang zu erhalten

Abstract

The use of biomarkers for diagnostics of Alzheimer’s disease (AD) has increased over the last years in specialized care and experimental settings. With the possibly upcoming availability of disease-modifying therapeutic agents, the diagnostics and treatment of patients with cognitive impairment will change. Biomarkers will be used as theranostic markers for case finding. The development and evaluation of biomarkers can be framed in a phase model from preclinical studies through trials in expert center settings to the evaluation of biomarkers in primary care, up to testing the efficacy and the impact of biomarkers on the healthcare system. Hippocampal volumetry is the most accepted and in-depth tested biomarker for AD diagnostics and prediction of the course. Therefore, hippocampus volumetry is used to illustrate the phase model of biomarker development and present the milestones already achieved and questions still to be resolved.

Vorheriger Artikel Triple aim improvement for individuals, services and society in dementia care

Nächster Artikel Präventionsstrategien gegen Demenz

Albert MS, Dekosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:270–279CrossRefPubMedPubMedCentral

Anonymous (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95CrossRef

Ball MJ (1977) Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. A quantitative study. Acta Neuropathol 37:111–118CrossRefPubMed

Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95CrossRef

Bobinski M, De Leon MJ, Wegiel J et al (2000) The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer’s disease. Neuroscience 95:721–725CrossRefPubMed

Boccardi M, Ganzola R, Bocchetta M et al (2011) Survey of protocols for the manual segmentation of the hippocampus: preparatory steps towards a joint EADC-ADNI harmonized protocol. J Alzheimers Dis 26(Suppl 3):61–75PubMed

Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259CrossRefPubMed

Brueggen K, Dyrba M, Barkhof F et al (2015) Basal forebrain and hippocampus as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment – A multicenter DTI and volumetry study. J Alzheimers Dis 48:197–204CrossRefPubMed

Clerx L, Van Rossum IA, Burns L et al (2013) Measurements of medial temporal lobe atrophy for prediction of Alzheimer’s disease in subjects with mild cognitive impairment. Neurobiol Aging 34:2003–2013CrossRefPubMed

10.

De Leon MJ, George AE, Stylopoulos LA et al (1989) Early marker for Alzheimer’s disease: the atrophic hippocampus. Lancet 2:672–673CrossRefPubMed

11.

De Leon MJ, Golomb J, George AE et al (1993) The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. AJNR Am J Neuroradiol 14:897–906PubMed

12.

Frisoni GB, Jack CR Jr., Bocchetta M et al (2015) The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. Alzheimers Dement 11:111–125CrossRefPubMed

13.

Galluzzi S, Geroldi C, Ghidoni R et al (2010) The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. J Neurol 257:2004–2014CrossRefPubMed

14.

Gosche KM, Mortimer JA, Smith CD et al (2002) Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 58:1476–1482CrossRefPubMed

15.

Hampel H, Prvulovic D, Teipel S et al (2011) The future of Alzheimer’s disease: the next 10 years. Prog Neurobiol 95:718–728CrossRefPubMed

16.

Jack CR Jr., Dickson DW, Parisi JE et al (2002) Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 58:750–757CrossRefPubMedPubMedCentral

17.

Kesslak JP, Nalcioglu O, Cotman CW (1991) Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer’s disease. Neurology 41:51–54CrossRefPubMed

18.

Mckhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269CrossRefPubMedPubMedCentral

19.

Panza F, Seripa D, Solfrizzi V et al (2016) Emerging drugs to reduce abnormal beta-amyloid protein in Alzheimer’s disease patients. Expert Opin Emerg Drugs. doi:10.1080/14728214.2016.1241232 PubMed

20.

Pepe MS, Cai T, Longton G (2006) Combining predictors for classification using the area under the receiver operating characteristic curve. Biometrics 62:221–229CrossRefPubMed

21.

Pepe MS, Etzioni R, Feng Z et al (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93:1054–1061CrossRefPubMed

22.

Risacher SL, Saykin AJ, West JD et al (2009) Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 6:347–361CrossRefPubMedPubMedCentral

23.

Schuff N, Woerner N, Boreta L et al (2009) MRI of hippocampal volume loss in early Alzheimer’s disease in relation to ApoE genotype and biomarkers. Brain 132:1067–1077CrossRefPubMedPubMedCentral

24.

Teipel S, Drzezga A, Grothe MJ et al (2015) Multimodal imaging in Alzheimer’s disease: validity and usefulness for early detection. Lancet Neurol 14:1037–1053CrossRefPubMed

25.

Teipel SJ, Keller F, Thyrian JR et al (2017) Hippocampus and basal forebrain volumetry for dementia and mild cognitive impairment diagnosis: could it be useful in primary care? J Alzheimers Dis 55:1379–1394CrossRefPubMed

26.

Thyrian JR, Fiss T, Dreier A et al (2012) Life- and person-centred help in Mecklenburg-Western Pomerania, Germany (DelpHi): study protocol for a randomised controlled trial. Trials 13:56CrossRefPubMedPubMedCentral

27.

Varon D, Barker W, Loewenstein D et al (2015) Visual rating and volumetric measurement of medial temporal atrophy in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort: baseline diagnosis and the prediction of MCI outcome. Int J Geriatr Psychiatry 30:192–200CrossRefPubMed

28.

Wolf D, Bocchetta M, Preboske GM et al (2017) Reference standard space hippocampus labels according to the EADC-ADNI harmonized protocol: Utility in automated volumetry. Alzheimers Dement. doi:10.1016/j.jalz.2017.01.009 PubMed

Titel: Translation of imaging biomarkers from clinical research to healthcare
verfasst von: Dr. Ingo Kilimann
Jochen René Thyrian
Wolfgang Hoffmann
Stefan J. Teipel
Publikationsdatum: 12.04.2017
Verlag: Springer Medizin
Erschienen in: Zeitschrift für Gerontologie und Geriatrie / Ausgabe Sonderheft 2/2017
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI: https://doi.org/10.1007/s00391-017-1225-3

Springerpflege

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 2/2017

Dementia care management in primary care

Autofahren und Demenz

Putting dementia awareness into general practice

Menschen mit Demenz in der primärärztlichen Versorgung

Triple aim improvement for individuals, services and society in dementia care

Subjective memory impairment in general practice